Welcome to our dedicated page for Aimei Health Technology Co., Ltd. SEC filings (Ticker: AFJK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aimei Health Technology Co., Ltd. filings document the regulatory record of a Cayman Islands blank-check company with ordinary shares, units and rights registered for Nasdaq trading. The filings describe SPAC mechanics such as trust-account funding, redemption-related timelines, deadline extensions, shareholder voting procedures and amendments to governing documents.
Recent 8-K, proxy and late-filing records also disclose direct financial obligations, unsecured promissory notes used to fund extension payments, capital-structure terms, material agreements, Nasdaq listing-compliance notices, delayed annual-report reporting and governance matters associated with the company's initial business-combination process.
Aimei Health Technology Co., Ltd., a SPAC focused on healthcare innovation, reported a small net loss of $37,704 for the six months ended June 30, 2026, as general, administrative and operational costs of $254,332 exceeded $216,628 of interest income on cash held in its trust account.
Assets totaled $12.53 million, including $12.49 million in the Trust Account and only $1,466 of operating cash, alongside a working capital deficit of $3.79 million and $2.20 million of related-party extension loans. As of June 30, 2026, 1,040,332 public shares were classified as redeemable at $12.00 per share, with an additional 2,126,000 non-redeemable ordinary shares outstanding.
The company terminated its previously agreed Business Combination Agreement with United Hydrogen on July 7, 2026, so that transaction will not close, and it continues to search for a new target. Management disclosed substantial doubt about the ability to continue as a going concern if no business combination is completed by the extended deadline, and also reported a material weakness in internal controls related to inadequate segregation of duties and insufficient written procedures.
Aimei Health Technology Co., Ltd. has a significant shareholder group led by First Trust entities. As of April 30, 2026, First Trust Merger Arbitrage Fund (VARBX) held 649,911 Ordinary Shares, representing 20.53% of Aimei’s outstanding Ordinary Shares. First Trust Capital Management L.P. (FTCM), together with First Trust Capital Solutions L.P. (FTCS) and FTCS Sub GP LLC (Sub GP), collectively reported beneficial ownership of 680,000 Ordinary Shares, or 21.48% of the class.
FTCM acts as investment adviser to various client accounts, including VARBX, with authority to purchase, vote and dispose of Aimei shares. FTCS and Sub GP are described as control persons of FTCM and may be deemed beneficial owners of the reported shares, although they do not hold Aimei shares for their own accounts. All reporting persons indicate sole voting and dispositive power over their respective reported holdings, with no shared voting or dispositive power.
Aimei Health Technology Co., Ltd deposited $34,330.96 into its trust account for public shareholders, equal to the lesser of $80,000 in total or $0.033 per outstanding public share for a monthly extension. This extends the deadline to consummate its initial business combination from August 6, 2026 to September 6, 2026, representing the company’s 21st permitted extension.
To fund this payment, Aimei Health issued an unsecured, non‑interest‑bearing promissory note for $34,330.96 to Aimei Health Ltd, due upon completion of its business combination with United Hydrogen. The payee may convert the note into private units at $10.00 per unit, each unit including one ordinary share and a right to receive one‑fifth of an ordinary share, by giving written notice at least two business days before closing.
W. R. Berkley Corporation filed an amended Schedule 13G/A regarding its position in Aimei Health Technology Co., Ltd, whose securities are ordinary shares with par value $0.0001 per share, CUSIP G01341109.
The filing states that W. R. Berkley Corporation, including subsidiary Berkley Insurance Company, beneficially owns 0 shares of Aimei Health Technology and holds 0.0% of the class. It reports no sole or shared voting or dispositive power over any shares, indicating ownership of five percent or less of the class. The certification is signed by Executive Vice President and Chief Financial Officer, and by Executive Vice President and Treasurer.
Aimei Health Technology Co., Ltd. has terminated its planned business combination with United Hydrogen Group Inc. and related Cayman entities. The company sent a termination notice on July 7, 2026 under Section 9.1(b) of the Business Combination Agreement after the deal failed to close by the applicable outside date.
As a result, the Business Combination Agreement, originally signed on June 19, 2024 and amended on June 6, 2025, is no longer in effect and the proposed transaction will not be consummated. Aimei’s CEO stated the company remains confident in finding a compelling future transaction.
Aimei Health Technology Co., Ltd extended the deadline to complete its initial business combination by one month, moving the termination date from July 6, 2026 to August 6, 2026. To do this, the company deposited $34,330.96 into its trust account for public shareholders.
The deposit equals the lesser of $80,000 for all outstanding public shares or $0.033 per public share for the month and represents the twentieth permitted extension. This amount is funded by an unsecured, non‑interest‑bearing promissory note to Aimei Health Ltd, which may be converted into private units at $10.00 per unit immediately before closing the planned business combination with United Hydrogen.
Aimei Health Technology Co., Ltd. director Daniel Veikko Polvi filed an initial Form 3, which is a statement of beneficial ownership for insiders. The filing shows no reportable transactions, with zero shares reported as bought, sold, or otherwise transacted in this excerpt.
Aimei Health Technology Co., Ltd. reports a board change. On June 24, 2026, director Julianne Huh resigned for personal reasons, with no disagreement on the company’s operations, policies, or practices. She confirmed all compensation has been paid and released the company from any related claims.
On June 29, 2026, the board appointed Daniel Veikko Polvi as a new director. He holds an MBA from Norwegian Business School and has served since May 2019 as managing director of Shearwater Limited, providing business management and strategic consulting services to international corporations. The company states there are no family relationships or related-party transactions requiring disclosure.
Aimei Health Technology Co., Ltd. reported Q1 2026 results as a SPAC still seeking to close its initial business combination. For the three months ended March 31, 2026, it recorded net income of $45,440, driven by $107,424 of interest on cash held in the Trust Account and offset by $61,984 of general, administrative and operational costs.
As of March 31, 2026, cash in the operating account was $18,516 with $12,276,196 held in the Trust Account and a working capital deficit of about $3,499,377. A total of 1,040,332 ordinary shares were classified as subject to possible redemption at a redemption value of $11.80 per share, alongside 2,126,000 non-redeemable ordinary shares.
The company has a pending Business Combination Agreement with United Hydrogen and notes that completion remains subject to conditions, including China Securities Regulatory Commission approval. Management discloses substantial doubt about its ability to continue as a going concern if a business combination is not completed by the July 6, 2026 combination deadline.
Aimei Health Technology Co., Ltd deposited an Extension Payment of $34,330.96 into its trust account to extend the deadline to complete its initial business combination by one month, moving the Termination Date from June 6, 2026 to July 6, 2026.
To fund this nineteenth extension, the company issued an unsecured promissory note dated June 4, 2026 to its sponsor Aimei Health Ltd and United Hydrogen Group Inc., with each contributing $17,165.48. The note bears no interest and is due upon completion of the planned business combination with United Hydrogen, and the payees may optionally convert the principal into private units at $10.00 per unit immediately before closing.